The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer.
E. E. Voest
No relevant relationships to disclose
N. Snoeren
No relevant relationships to disclose
S. B. Schouten
No relevant relationships to disclose
A. M. Bergman
No relevant relationships to disclose
E. van Werkhoven
No relevant relationships to disclose
O. J. L. Loosveld
No relevant relationships to disclose
T. M. van Gulik
No relevant relationships to disclose
J. M. Smit
No relevant relationships to disclose
A. Cats
No relevant relationships to disclose
E. Boven
No relevant relationships to disclose
E. Hesselink
No relevant relationships to disclose
A. Rijken
No relevant relationships to disclose
M. Tol
No relevant relationships to disclose
O. Dalesio
No relevant relationships to disclose
H. M. Verheul
No relevant relationships to disclose
R. A. Tollenaar
No relevant relationships to disclose
J. van der Sijp
No relevant relationships to disclose
I. Borel Rinkes
No relevant relationships to disclose
R. van Hillegersberg
No relevant relationships to disclose